细胞命运决定及人类重大疾病
研究方向一、建立利用转分化/重编程技术获得人源疾病细胞模型,探索疾病发病机理和基于发病机理的治疗新策略
研究方向二、细胞表面蛋白复合体作为老年痴呆症新靶点及相关治疗新策略
研究方向三、针对神经精神疾病的多病因特点,探索多靶点系统治疗新策略
Cell signaling and translational research on complex diseases
1. Using novel transdifferentiation / reprogramming technology to establish human disease model and use thereof to explore the pathogenesis mechanisms and new therapeutic strategies.
2. Cellular membrane protein complexes as the novel targets against a new target for Alzheimer's disease and related drug discovery
3. Systematic (multi-targets) therapeutic strategies for complex neuropsychiatric disorders.
美高梅转化医学高等研究院研究员
美高梅附属东方医院干细胞转化医学产业基地副主任
干细胞制备与质检平台主任
Principle investigator, Division of Translational medicine, Institute for Advanced Study, Tongji University
Director, Stem cell core facility, Shanghai East Hospital
Deputy director, Translational Medical Center for Stem Cell Therapy, Shanghai East Hospital
1996年毕业于复旦大学遗传学及遗传工程系获学士学位,1999年于中科院上海细胞生物学研究所获细胞学硕士学位,2000年9月赴德留学,2004年以全优最高分(summa cum laude)毕业于德国海德堡大学(The Ruperto-Carola University of Heidelberg)生物学系获理学博士学位。2007-2016年在中科院上海生科院生化细胞所任副研究员。2015年6月起承担美高梅附属东方医院干细胞制备质检平台GMP规范化建设。2016年加入美高梅转化医学高等研究院。已在国际知名专业学术刊物上已发表论文39篇,其中通讯作者17篇,第一作者13篇,第一作者和通讯作者论文总影响因子IF超过200,第一作者单篇最高他引297,通讯作者单篇最高他引96,第一作者与通讯作者论文总他引近两千次,科学家影响力H-index为20。已申请发明专利12项,其中国际发明专利4项,已有4项获得中国发明专利授权,1项获得美国发明专利授权。2007年入选上海市浦江人才计划。2011年获上海市科技进步一等奖。2015年获中华医学科技奖二等奖。
2007年2月回国至今主要从事重要信号转导通路在细胞命运决定和重大疾病发生发展中的分子机理的研究,先后在细胞重编程及体细胞转分化实现与调控、老年痴呆症及二型糖尿病等人类重大疾病发生发展的分子细胞学新机制的探索上取得了一系列重大进展,包括建立了一系列体外小分子诱导转分化的体系,提出了转分化的可能通式;进行了神经发生、淀粉样蛋白生成特异调控等全新机理探索,揭示了通过干预和调控各种参与调控β淀粉样蛋白的产生和代谢的细胞表面蛋白复合体的功能抑制老年痴呆症进程的新途径,从而提示了神经退行性疾病新的分子细胞学基础及相关的治疗新策略等。目前主持的干细胞制备质检平台已完成国家干细胞临床研究机构报备,已有8项干细胞相关临床研究在平台开展。
Major scientific contributions:
We are focusing on the molecular mechanisms of signal transduction pathways involved in the cell reprogramming and transdifferentiation and the use there of in neurodegeneration diseases. The substantial progress of my research work includes: the establishment of a series of in vitro transdifferentiation system using small molecules, novel strategies against the Alzheimer’s disease by promoting neurogenesis, specifically inhibit amyloid generation by targeting holo secretase complexes, etc. I have published 24 research articles in prestigious peer-reviewed journals as corresponding author or first author. I have finished 11 applications for invention patents, four of which have been authorized by China, one by the United States. Since June 2015, I lead the GMP core facility for Stem Cell Engineering, Translational Medical Center for Stem Cell Therapy, Shanghai East Hospital, School of Medicine, Tongji University. 8 clinical trails of stem cells application are being developed on our platform. I have been awarded for Pujiang Talent (2007), Shanghai Scientific
|